-

Trinity Life Sciences Acquires CBPartners

Acquisition Significantly Bolsters Trinity’s Value, Access and Pricing Business

WALTHAM, Mass.--(BUSINESS WIRE)--Trinity Life Sciences, a leader in global life sciences commercialization solutions, announced the acquisition of New York-headquartered CBPartners. The acquisition significantly scales Trinity’s Value, Access and Pricing business, adding over 75 dedicated experts to the Company. This level of depth and breadth in market access gives Trinity a leading position in the life sciences industry. The combination of Trinity’s commercial strategy and solutions, augmented by CBPartners’ expertise in the value, access and pricing space, will better empower life sciences companies to commercialize their innovations and ensure access for patients.

“CBPartners’ focus on global pharmaceutical pricing and market access issues will be enhanced by Trinity’s commercial strategy heritage and real-world data,” said Mónica Martín de Bustamante, CEO & Managing Director of CBPartners. “We are excited to offer the additional services in the Trinity portfolio – commercial strategy, launch planning, market research, forecasting, benchmarking, etc. – to our client base so we can develop stronger cross-functional strategies that demonstrate a product’s value. It is exciting to be part of the Trinity team.”

“We are thrilled to have CBPartners join our team,” said David Fitzhenry, CEO of Trinity Life Sciences. “Pricing and access issues have been the Achilles’ heel of many recent drug launches. With the addition of CBPartners, Trinity is better poised to help our clients revolutionize the commercial model and provide their drugs to patients around the world. The addition of CBPartners will also broaden our work in emerging markets allowing us to assist our clients on a more global scale.”

CBPartners’ senior leadership and staff will remain on with Trinity, and the addition of the CBPartners consultants will significantly expand Trinity’s footprint in New York City, San Francisco and London. The aligned cultures and values of both companies reflect an evidence-first approach to helping clients make critical business decisions.

About CBPartners

CBPartners is a leading global healthcare strategy consulting firm. The company serves a variety of clients ranging from global pharmaceutical/biopharmaceutical companies to ministries of health in emerging markets. CBPartners solves clients’ most challenging issues, including value, access, pricing, portfolio design, launch strategy, partnership strategy and policy development.

About Trinity Life Sciences

Trinity Life Sciences is a trusted strategic commercialization partner, providing evidence-based solutions for the life sciences. With over 20 years of experience, Trinity is committed to solving clients’ most challenging problems through exceptional levels of service, powerful tools and data-driven insights. Trinity’s range of products and solutions includes industry-leading benchmarking solutions, powered by TGaS Advisors. To learn more about how Trinity is elevating life sciences and driving evidence to action, visit trinitylifesciences.com.

Contacts

Elizabeth Marshall
Trinity Life Sciences
781-577-6376
emarshall@trinitylifesciences.com

Trinity Life Sciences


Release Summary
Trinity Life Sciences acquires CBPartners.
Release Versions

Contacts

Elizabeth Marshall
Trinity Life Sciences
781-577-6376
emarshall@trinitylifesciences.com

More News From Trinity Life Sciences

Trinity Appoints Scott Evangelista as CEO to Lead Next Chapter

WALTHAM, Mass.--(BUSINESS WIRE)--Trinity, a global leader in technology-enabled commercialization solutions for the life sciences industry, today announced Scott Evangelista has been appointed Chief Executive Officer, succeeding Leslie Orne who is stepping down after three years as CEO and over 24 years with the company. Ms. Orne will transition to the role of Senior Advisor and serve as a member of Trinity’s Board of Directors. Over her distinguished tenure, Ms. Orne helped guide Trinity’s evo...

GSK, Amgen and AstraZeneca Lead the Pack in Trinity’s 2025 Digital Marketing Competency Report

WALTHAM, Mass.--(BUSINESS WIRE)--Trinity, a leader in global life sciences commercialization, today announced the release of its 5th Annual TGaS Digital Marketing Competency Report, a three-part series benchmarking the digital marketing presence of more than 150 biopharma brands. The 2025 edition reveals a significant leap forward in the industry’s digital sophistication, with a 19% increase in Proficient brands and a surge of innovation in patient engagement strategies. The report ranks each b...

Trinity Expands Global Footprint with Acquisition of EVERSANA’s APACME Advisory Services

WALTHAM, Mass.--(BUSINESS WIRE)--Trinity, a leader in global life sciences commercialization solutions and recognized for being a strategic, tech-enabled commercialization company that empowers pharma, biotech, and medtech organizations to advance medical innovations, announced today the acquisition of EVERSANA’s advisory services operation in Asia-Pacific and the Middle East (APACME). The strategic acquisition will transition EVERSANA’s advisory services operation in APACME to Trinity, further...
Back to Newsroom